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Objectives: To evaluate the relative cost-effectiveness
of introducing the RTS,S malaria vaccine in sub-
Saharan Africa compared with further scale-up of
existing interventions.
Design: A mathematical modelling and cost-
effectiveness study.
Setting: Sub-Saharan Africa.
Participants: People of all ages.
Interventions: The analysis considers the introduction
and scale-up of the RTS,S malaria vaccine and the
scale-up of long-lasting insecticide-treated bed nets
(LLINs), indoor residual spraying (IRS) and seasonal
malaria chemoprevention (SMC).
Main outcome measure: The number of
Plasmodium falciparum cases averted in all age groups
over a 10-year period.
Results: Assuming access to treatment remains
constant, increasing coverage of LLINs was
consistently the most cost-effective intervention across
a range of transmission settings and was found to
occur early in the cost-effectiveness scale-up pathway.
IRS, RTS,S and SMC entered the cost-effective
pathway once LLIN coverage had been maximised. If
non-linear production functions are included to capture
the cost of reaching very high coverage, the resulting
pathways become more complex and result in selection
of multiple interventions.
Conclusions: RTS,S was consistently implemented
later in the cost-effectiveness pathway than the LLINs,
IRS and SMC but was still of value as a fourth
intervention in many settings to reduce burden to the
levels set out in the international goals.
INTRODUCTION
Following the adoption of the Millennium
Development Goals (MDGs) in 2000, the
concurrent targets of increasing the propor-
tion of children under 5 years that sleep
under a bed net and that have access to
appropriate antimalarial drugs1 have been
associated with an estimated 37% decline in
malaria case incidence and 60% decline in
malaria mortality.2 3 These gains have been
achieved with substantial investment in
malaria which has more than doubled over
the last decade, from less than $1 billion in
2005 to over $2.5 billion in 2015.2 However,
since 2011, the acceleration in funding has
slowed, plateauing in recent years.2 Funding
gaps therefore remain an inevitable issue for
future control and elimination efforts and
thus optimising the use of available resources
is paramount. Within this context, new inter-
ventions must be evaluated not only on their
direct cost-effectiveness, but comparative to
the other intervention options.
Key questions
What is already known about this topic?
We sought to evaluate the relative cost-effectiveness
of introducing the RTS,S malaria vaccine in
sub-Saharan Africa compared with further scale-up
of existing interventions. We did not identify any
studies modelling the impact and costs of interven-
tion packages with respect to scaling-up coverage.
What are the new findings?
We find that implementing the RTS,S malaria
vaccine generally only enters the optimal pathway of
scale-up of interventions once very high coverage
of vector control interventions, along with seasonal
malaria chemoprevention in settings where it is
recommended, has been achieved.
Recommendations for policy
While the RTS,S malaria vaccine can be an effective
tool for reducing burden, enhancing coverage of
vector control should generally remain of higher pri-
ority across sub-Saharan Africa. This is particularly
the case within settings where universal coverage of
long-lasting insecticide-treated nets has not yet
been achieved.
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In early 2015, the ﬁnal results from the large phase III
trial of the RTS,S malaria vaccine across 11 sites in
Africa were published.4 Reported efﬁcacy against clinical
and severe malaria disease in the presence of high use
of bed nets for prevention and alongside a high level of
access to care was moderate. The trial reported 36.3%
(95% CI 31.8% to 40.5%) efﬁcacy against clinical
disease in children aged 5–17 months over 4 years
under a four-dose schedule and 32.2% (13.7% to
46.9%) efﬁcacy against severe disease.4 Nevertheless, in
the high transmission sites contributing most of the
disease episodes, there was a signiﬁcant public health
impact, with between 1000 and 6000 cases estimated per
1000 population over 4 years of follow-up in the six
higher transmission sites.4 To estimate the wider public
health impact and cost-effectiveness of the vaccine in
settings representative of current levels of ongoing
malaria transmission, a WHO working group was
formed to compare the outputs from four mathematical
models parameterised using the trial data. The results
from this comparison demonstrated that the vaccine
could have a substantial public health impact across set-
tings ranging from 10% to 60% parasite prevalence in
2–10 year olds.5 Furthermore, assuming a midrange cost
of $5 per dose under a four-dose schedule, the vaccine
was considered to be highly cost-effective (incremental
cost-effectiveness ratio (ICER) of $44–$279 per
disability-adjusted life year (DALY)) within these same
transmission levels.5
Existing malaria interventions are also highly cost-
effective.6 Although there are substantial differences
between the methodologies used to make these esti-
mates, a 2011 study estimated the median ICER per
DALY at $27 (range $8.15–110) for long-lasting
insecticide-treated nets (LLINs) and $143 (range
$135–150) for indoor residual spraying (IRS), while
for seasonal malaria chemoprevention (SMC), the cost
per case averted has been estimated at $68 (95% CI
$62 to $75), similar to comparable metrics for LLINs
and IRS.7 Thus, in areas in which coverage of these
interventions is not yet universal, it is important to
understand the relative cost-effectiveness of the full
suite of interventions and where the RTS,S malaria
vaccine could contribute. Importantly, this needs to
take into account the diminishing marginal returns
associated with the scale-up of interventions that may
lead to a higher unit cost at high levels of
coverage.8 9
Here, we use a well-established transmission model for
Plasmodium falciparum malaria and its associated inter-
ventions10 to estimate the cost and impact of different
intervention packages at varying levels of scale-up. We
evaluate these packages over a wide range of transmis-
sion settings and use the estimates to derive the most
cost-effective pathways for scaling-up malaria interven-
tions in order to inform decisions about the introduc-
tion of the RTS,S malaria vaccine.
METHODS
Transmission and intervention model
We used an established model of P. falciparum malaria
transmission that incorporates the full suite of interven-
tions.10 In brief, individuals that are initially susceptible
are exposed to infection with P. falciparum malaria from
bites of infectious mosquitoes. The rate at which suscep-
tible individuals become infected is inﬂuenced by mos-
quito density and infectivity and is moderated by
immunity. Infants are partially protected for the ﬁrst
6 months of their life by passively acquired maternal
immunity and individuals acquire natural immunity with
repeated exposures through time. Infected individuals
may be treated, after which follows a period of prophy-
laxis before returning to the susceptible class. Infected
individuals can develop clinical disease,11 which may
progress to severe disease and possibly death.12 A pro-
portion of infected individuals harbour asymptomatic
infections, some of which may also be subpatent. The
model explicitly incorporates mosquito-population
dynamics,13 allowing the modelling of various protective,
repellent and killing aspects of the vector-control inter-
ventions. We adopt the same methodology for incorpor-
ating the RTS,S vaccine into the model as used for a
large model-comparison exercise.5 The RTS,S vaccine
model dynamics use a biphasic antibody decay model
ﬁtted to the phase III individual-level trial data, allowing
the level of protection against clinical disease to be cap-
tured with respect to antibody titre postvaccination.14
Transmission settings
To capture the range of transmission settings across
Africa, we generated a baseline set of ‘strata’. These
were characterised by the parasite prevalence in the
absence of interventions other than treatment, the
annual seasonal pattern of transmission and the mos-
quito vector species present and their associated bio-
nomics (which affect the predicted impact of LLINs and
IRS). The mean parasite prevalence over the full year in
2–10 year-olds (PfPR2_10) was simulated in 17 bands
between 0.1% and 80% to capture the range of transmis-
sion levels observed prior to intervention scale-up.3 Four
seasonality proﬁles were simulated based on
Fourier-transformed average rainfall patterns obtained
from satellite data between 2003 and 2006:15 (A) highly
seasonal—with a single strong peak in rainfall character-
istic of the Sahel region; (B) seasonal—with a less strong
peak in rainfall characteristic of West Africa coastal
areas; (C) bimodal—with one large and a second
smaller peak in rainfall characteristic of East and
Southern Africa; and (D) non-seasonal characteristic of
perennial levels of rainfall observed in Central Africa.
The four mosquito vector proﬁles capture behavioural
difference in the levels of anthropophagy (the human
biting index), endophily (indoor biting), endophagy
(indoor resting) and the timing of bites relative to sleep-
ing hours. Rather than simulating species and their
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combinations, these proﬁles represent a range of vector
species bionomics moving from behaviours associated
with Anopheles gambiae s.s./Anopheles funestus to those
associated with Anopheles arabiensis. The combination of
parasite prevalence bands, seasonality of transmission
and vector bionomics resulted in 272 baseline strata.
Further details are provided in the online
supplementary materials.
Interventions
For each strata, we simulated the impact of all possible
applicable combinations from a set of four interventions
(LLINs, IRS, SMC and RTS,S) at a range of coverage
levels (see online supplementary materials for details),
resulting in a total of 306 000 simulations. Throughout
we assumed that an LLIN would cover 1.8 people (con-
sistent with the approach taken in the World Malaria
Report2) and that nets would be distributed on a
3-yearly cycle. The bed net model further captures loss
of adherence, decay in insecticides and wear-and-tear
over time16 and we deﬁne coverage of bed nets as usage
as reported in DHS/MIS surveys.17 18 For IRS, we
assumed that a DDT-like insecticide was used and
applied once a year. For this intervention, coverage was
deﬁned as the proportion of the population residing in
a house that was sprayed in the previous year. SMC was
simulated following WHO recommendations to children
between 6 months and 5 years of age, with 3 monthly
doses of SP-amodiaquine in seasonal settings, with the
second dose timed to occur at the seasonal peak in
transmission.19 Coverage was deﬁned as the proportion
of eligible children who received all three doses and we
did not model the effect of partial doses. Following the
recent WHO recommendations, we considered a four-
dose vaccine schedule in children aged 5–27 months.
We assumed children would be vaccinated at 6, 7.5 and
9 and 27 months, with the timings of the ﬁrst doses
chosen to coincide with other contacts with healthcare
at 6 and 9 months. Coverage was deﬁned as the propor-
tion of eligible children receiving the full four doses. A
20% drop off between those receiving the ﬁrst three
does and the fourth dose was included to capture loss of
follow-up.5
Receipt of a single intervention was assumed to be cor-
related across the population. When two or more inter-
ventions were included, we explored two options: no
correlation in receipt (ie, independent random distribu-
tion of both interventions) or full correlation (ie, those
that receive the ﬁrst intervention are will also receive the
second). Throughout we assumed that 60% of those
with clinical disease received prompt and effective ﬁrst-
line treatment.
Costing
In the absence of detailed country-level data for all inter-
ventions, we adopted a unit costing approach. These
were derived from the literature and inﬂated to 2015
US$ (table 1).
We considered two approaches for costing increasing
coverage of the four interventions. The ﬁrst approach
assumed increases in coverage were associated with
linear increases in cost, while in the second approach,
we derived non-linear relationships between coverage
and unit costs. For this second approach, the number of
nets required to achieve a given coverage level (deﬁned
by usage) was obtained from Bhatt et al,27 assuming a
net-retention half-life of 3 years and the business-as-usual
net allocation process. We estimated similar health pro-
duction functions for IRS, SMC and the vaccine by
ﬁtting a model to data relating the cost and coverage of
these interventions in a Bayesian framework (see online
supplementary materials for full details). The total cost
(P) of delivering an intervention to an individual is
assumed to consist of two components: the commodity
cost (U) and the delivery cost (D)
P ¼ U þ D
The commodity cost remains ﬁxed per person (under
the assumption that economies of scale have been
reached) with respect to coverage (C). The delivery cost
per person is ﬁxed at a baseline amount, N, until cover-
age reaches a given threshold, Cτ, above which the deliv-
ery costs increase logarithmically
D ¼ N when C  Ct




We considered a number of outcome measures to evalu-
ate the incremental cost-effectiveness of each interven-
tion. The primary outcome measure presented
throughout is the number of cases averted over a 10-year
period. Other outcome measures considered include
the DALYs averted and the number of cases averted in
children aged 6 months–5 years old and over a 10-year
period (see online supplementary materials for more
details on calculation).




LLINs 7.03 per LLIN
delivered
White et al.20 The 2009
costing was not inflated
as more recent
estimates are similar21
IRS 5.41 per person
protected
PMI AIRS project22




RTS,S 39.25 per fully
vaccinated child
Under the assumption
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Estimating cost-effective scale-up
For each transmission strata, the cost-effective scale-up of
interventions was estimated using the following steps: (i)
start with 0% usage/coverage of all interventions, (ii) for
each available intervention, calculate the ICER of scaling
up to the next usage/coverage level, (iii) implement the
step with the lowest associated ICER (the most cost-
effective), (iv) repeat the process (i–iii) until the scale-up
of all interventions has been maximised or elimination is
achieved. This process is summarised in ﬁgure 1. It
should be noted that while this approach results in the
most cost-effective next level of intervention coverage,
the resulting intervention packages are not necessarily
maximally efﬁcient for a given budget since this reﬂects
a gradient descent optimisation (stepwise) rather than a
multidimensional optimisation approach. Nevertheless, it
is used here to illustrate the pathways at each point in the
absence of deﬁned budget limits.
Cost sensitivity analysis
We assessed the sensitivity of the order of scale-up to
uncertainty in the costs of interventions and their asso-
ciated production functions. The analysis was repeated
with 100 random draws from the posterior predictive
interval for the IRS, SMC and RTS,S production func-
tions. LLIN costs were randomly drawn from the interval
between the least optimistic (net retention half-life of
2 years and current allocation process) and most opti-
mistic (net retention half-life of 3 years and improved
allocation process) net-allocation models.27 For each 100
runs and across all transmission strata, the relative occur-
rence of each intervention at each scale-up step was
measured.
The sensitivity of the scale-up order to the assumed $5
per dose cost of the vaccine was also examined by incre-
mentally decreasing its price (increases were not
included, given the initial results). At each step, the
proportion of settings where the vaccine appeared in
the pathway before LLINs, IRS and SMC was then
recorded.
RESULTS
Figure 2 shows the scale-up pathways for the combin-
ation of the four interventions across a range of trans-
mission levels characterised by their baseline PfPR2–10
(in the absence of interventions other than treatment of
clinical cases). For the majority of settings, across the
full-range of baseline PfPR2–10, for vector bionomics
characteristic of the three main species found in Africa
(A. gambiae s.s., A. arabiensis and A. funestus) and for sea-
sonal and non-seasonal settings, LLINs appear ﬁrst in
the most cost-effective pathway. At baseline PfPR2–10
<5%, LLINs and RTS,S are predicted to reduce ongoing
transmission to pre-elimination levels. If scale-up of
these interventions is unable to achieve pre-elimination
transmission levels, our results suggest that LLINs
should be scaled up to very high usage levels (75%)
prior to introducing additional interventions if cost-
effectiveness is the single deciding factor. After this level
has been achieved, in non-seasonal settings, IRS is the
second-most cost-effective intervention at lower baseline
PfPR2–10 (5%< PfPR2–10 <65%), while RTS,S is estimated
to be the second most cost-effective intervention in set-
tings with baseline PfPR2–10 ≥65%. In seasonal settings,
SMC is generally the second most cost-effective interven-
tion to introduce prior to IRS or RTS,S.
The results shown in ﬁgure 2 assume a single unit cost
that does not change with increasing coverage. However,
as higher coverage levels are sought, costs tend to
increase as it becomes more difﬁcult to ﬁll the remain-
ing coverage gaps and to access the hardest-to-reach
populations. Figure 3 shows our estimated empirical pro-
duction functions for IRS, SMC and vaccination (based
Figure 1 Schematic of the cost-effective scale-up pathway. For each transmission strata, the cost-effective scale-up of
interventions was estimated, starting with no intervention coverage then scaling up coverage based on the most favourable
incremental cost-effectiveness ratio. Scale-up ceased when all interventions were at full coverage or elimination had occurred.
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on DTP3 data) alongside the previously published esti-
mated for LLIN usage.27 All four functions have a
similar shape, with increasing costs at high coverage.
However, for IRS and SMC, the recorded coverage was
consistently high (>80%) and the limited number of
data points mean that this function is uncertain.
Including the non-linear production functions shown
in ﬁgure 3 leads to a substantially more complicated
pattern of scale-up pathways (ﬁgure 4). With these addi-
tional non-linearities, alternative interventions are always
introduced before LLIN usage is increased to the
maximum level due to the high estimated cost of achiev-
ing high LLIN usage. In non-seasonal settings, LLINs
are estimated to be the most cost-effective initial inter-
ventions. Across the majority of settings with baseline
5%<PfPR2–10<60%, IRS appears second with RTS,S also
introduced once moderate levels of IRS coverage have
been achieved. In seasonal settings, for baseline
PfPR2–10<50%, LLINs remain the ﬁrst most cost-
effective intervention. However, in settings with higher
baseline transmission, SMC and RTS,S appear earlier.
Following this, the second and third most cost-effective
additional interventions vary by setting, with IRS being
favoured in locations where the vector bionomics are
more amenable to insecticidal control, whereas RTS,S or
SMC are favoured in settings with less favourable vector
bionomics.
Figure 5 illustrates the translation of these generic
results to locations in sub-Saharan Africa using estimates
of vector species presence, baseline PfPR2–10 and season-
ality. Across the majority of settings, LLINs are the ﬁrst
most cost-effective intervention. Using the results from
ﬁgure 4, the LLIN usage at which a second intervention
is estimated to be more cost-effective than further LLIN
scale-up is shown in ﬁgure 4A. In the majority of settings,
we estimate a switch is cost-effective at 55–65% LLIN
usage, although in some seasonal areas in West Africa
and in areas with high estimated baseline PfPR2–10, other
interventions are estimated to be more cost-effective at
lower levels of LLIN usage. This threshold is similar to
the levels of usage that have now been achieved in many
parts of Africa (ﬁgure 5B).
While the results vary for different assumed unit costs
for each intervention, in a sensitivity analysis of these
costs, we found that the order of scale-up is generally
maintained (ﬁgure 6A). Since the price of the RTS,S
vaccine has not been released, we additionally assessed
the sensitivity to the assumed price per dose. Figure 6B
shows the proportion of scenarios in which RTS,S, at a
given price per dose, is estimated to occur before other
interventions in the scale-up pathway. In general, RTS,S
remains late in the pathway. However, this pattern
changes if the price per dose drops below US$3 where
the relative cost-effectiveness becomes comparable to
Figure 2 Costs-effective scale-up pathways with linear costs. Each row represents a cost-effective scale-up pathway for a
specific transmission setting (baseline PfPR2_10, seasonal profile, vector profile, intervention correlation) ordered by PfPR2_10 on
the y-axis. Interventions are scaled-up in the order reading along the row from left to right, with the fill colour representing the
intervention being scaled-up. Panels split the output into (A) non-seasonal settings and (B) seasonal settings, with the latter
including seasonal malaria chemoprevention as an option.
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IRS and SMC. However, even at a very low cost per dose
(<US$1.00), LLINs are estimated to remain a more cost-
effective intervention than RTS,S in approximately half
of the settings.
DISCUSSION
Our analysis demonstrates that LLINs remain the most
cost-effective ﬁrst intervention to reduce malaria trans-
mission across the broad range of transmission settings
observed in sub-Saharan Africa. The high consumption
and competitive market for LLINs has driven costs down
over the last 10 years.21 This, coupled with their dual
effect of personal-level and community-level protec-
tion,28 makes them highly cost-effective. This ﬁnding was
consistent for all outcome measures considered (see
online supplementary materials S1–S4). Furthermore,
our results indicate that, based on cost-effectiveness con-
siderations, the RTS,S vaccine should be considered a
secondary intervention alongside the two other
WHO-recommended malaria interventions for this
region—SMC and IRS. The recommended schedule for
the RTS,S vaccine that will be tested in pilot implemen-
tation is for four doses given in children aged
5–27 months, who constitute a small subset of the
exposed population. The vaccine offers partial protec-
tion to this group over a duration of ∼4 years.4 14 As a
result, this vaccine does not have the beneﬁt of inducing
herd-immunity in the population and is considerably
more expensive per person than the other interventions
considered here (at the assumed cost of $5 per dose),
lowering its relative cost-effectiveness. Thus, other than
Figure 3 Non-linear production functions. Production functions estimate the non-linear relationships between intervention usage
or coverage and the cost per person. (A) Cost per person protected by long-lasting insecticide-treated nets, taken from Bhatt
et al.27 Three scenarios: assuming current allocation model and a 3-year net-retention half-life, an improved allocation model and
3-year net retention half-life and a current allocation model and 2-year net retention half-life are shown by the solid black, dotted
grey and dashed grey lines, respectively. (B) DTP3 coverage as a function of the price per person (standardised by the cost of a
fully vaccinated child). (C) IRS coverage as a function of the cost per person protected based on President’s Malaria Initiative
data.22 (D) Seasonal malaria chemoprevention coverage as a function of the costs per child per dose based on Clinton Health
Access Initiative23 and Medicins San Frontiers estimates.24 For (B–D), black lines represent the best-fit model and shaded areas
the 95% prediction interval.
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Figure 4 Costs-effective scale-up pathways with non-linear costs. Each row represents a cost-effective scale-up pathway for a
specific transmission setting (baseline PfPR2_10, seasonal profile, vector profile, intervention correlation) ordered by PfPR2_10 on
the y-axis. Interventions are scaled-up in the order reading along the row from left to right, the fill colour representing the
intervention being scaled-up. Panels split the output into (A) non-seasonal settings and (B) seasonal settings, with the latter
including seasonal malaria chemoprevention as an option.
Figure 5 Long-lasting insecticide-treated net (LLIN) primary scale-up and usage statistics. (A) The LLIN usage at which an
alternative intervention is first introduced for sub-Saharan Africa. For much of sub-Saharan Africa, LLIN scale-up to medium or
high usage levels before any other intervention is implemented is the most cost-effective. In seasonal areas, indoor residual
spraying or seasonal malaria chemoprevention can be the first most cost-effective intervention. (B) The distribution of country
level LLIN usage estimates for 2015.3
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in high transmission settings where there is a high
burden of disease in young children, we ﬁnd that RTS,S
enters the cost-effectiveness scale-up pathway later on
when other potential options for reducing transmission
and/or protecting from disease are already maximised.
While increasing usage of LLINs is identiﬁed as the
most cost-effective ﬁrst intervention, once these levels
reach 50–60%, we estimate that the three alternative
interventions—IRS, SMC and RTS,S—become increas-
ingly competitive when comparing the relative cost-
effectiveness. This level of LLIN usage is similar to
the levels reported for many countries in sub-Saharan
Africa in 2015,3 suggesting that context-speciﬁc cost-
effectiveness considerations may become increasingly
important as investment in current or new interventions
are considered. The inclusion of IRS as a secondary
vector control option could further reduce onward trans-
mission through providing additional protection for
those that do not consistently use nets or over the
periods between net distribution rounds in which the
integrity of the net and/or efﬁcacy of the insecticide has
decayed. However, the trial data on the combination of
these two vector control interventions remain inconclu-
sive29 30 and hence close monitoring would be required
to fully understand the operational impact of their com-
bined use. Furthermore, any recommendations in favour
of vector control must be made in the light of current
and potential future insecticide resistance, the effects of
which were not included in this analysis. In a small
number of settings, characterised by a high level of sea-
sonal transmission and intense transmission, we identi-
ﬁed either SMC or IRS as the most cost-effective ﬁrst
intervention. SMC and IRS are temporally targeted at the
peak transmission season, and this therefore increases
their cost-effectiveness relative to non-seasonally targeted
interventions.31 A comparison of the impact of pairwise
combinations of interventions is included in online
supplementary material S5.
We explicitly excluded treatment scale-up options
from the cost-effectiveness analysis for several reasons.
First, treatment has been previously shown to be highly
cost-effective.6 Therefore, equitable access to treatment
for severe disease is an ethical priority and universal
scale-up of treatment coverage is important to preserve.
Second, while increasing treatment coverage, and there-
fore costs, affects the absolute cost-effectiveness of other
interventions (with lower treatment coverage making
them more cost-effective), the relative cost-effectiveness
when comparing interventions (and therefore scale-up
pathways) will be inﬂuenced far less. Third, the ability of
a country to increase coverage of treatment will depend
critically on health system capacity and hence vary geo-
graphically. Thus, a simple unit cost approach is unlikely
to be appropriate. For other interventions, the commod-
ities (particularly LLINs) are purchased through Global
Fund pathways for which there is a coordinated tender-
ing process. We have therefore adopted a unit costing
approach for the interventions considered in this broad-
scale comparison.
Systems-level inefﬁciencies,32 overallocation27 and sys-
tematic under-representation in hard-to-reach popula-
tions33 34 may all contribute to diminishing marginal
returns when investing in increasing the coverage of an
intervention to very high levels. Our results demonstrate
that it is important to capture these non-linearities when
considering the relative costs-effectiveness of introducing
new interventions such as the RTS,S malaria vaccine.
With the simple assumption that costs associated with
increasing the usage or coverage of an intervention
increases linearly, we observe a very clear picture of cost-
effective scale-up, with LLIN usage increased to the
maximum level (75%) in nearly all settings before any
Figure 6 Sensitivity of the results to variations in costs of the interventions. (A) The sensitivity of the scale-up pathway to
uncertainties in the health production functions determining the cost of each intervention. Columns represent 10 equally spaced
samples (from left to right) along the scale-up pathway. Numbered cells denote the number of instances, out of 100 realisations,
that a given intervention was implemented at that step. (B) Sensitivity of outcome to assumed cost per dose of RTS,S. The
assumed cost per dose was decreased in incremental amounts. At each step, the proportion of settings in which the RTS,S was
implemented before either long-lasting insecticide-treated nets, indoor residual spraying or seasonal malaria chemoprevention
(blue, red and yellow lines, respectively) is shown.
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other intervention is implemented. However, the inclu-
sion of non-linear productions functions that capture
the increasing cost associated with achieving high levels
of coverage of any given intervention leads to a more
complicated picture of the cost-effective scale-up
pathway. While there was considerable uncertainty in
our estimated production functions for each interven-
tion, general patterns in scale-up remained fairly robust
to this. However, further data on these patterns are crit-
ical to inform local planning. Subtle differences in the
inﬂection points of the production functions affect
when a switch between interventions is made. This is
especially of note for the SMC production function
where lack of data lead to considerable uncertainties in
the resultant production function.
While cost-based uncertainties were explored in this
analysis, we did not additionally explore the uncertainty
in model structure or parameterisation due to the com-
putational complexity in undertaking such an analysis.
Clearly, model parameters and structures could affect
the relative impact of interventions as well as the combi-
nations of interventions needed to reach pre-elimination
levels. Determining the cost-effective scale-up in a step-
wise manner informed by the ICER always chooses the
next most cost-effective option. This is analogous to a
gradual scale-up of interventions over time, where future
options are considered, given an established interven-
tion landscape. However, for a given spend, the resulting
intervention package estimated from a stepwise
approach may differ from a global optima if all scale-up
options were considered in unison.
Context-speciﬁc challenges to scaling-up a given inter-
vention will always be present and cannot be repre-
sented in this style of analysis. To this end, policy
decisions must take into account such challenges when
considering recommendations in a speciﬁc setting.
While a number of countries have achieved the high
levels of LLIN usage that our analysis suggests to be cost-
effective,3 in other settings, there may be barriers to
achieving and sustaining the levels in the long term,
nuancing the decision to target LLIN scale-up.
Nevertheless, the ambitious targets set by the WHO for
universal coverage may be integral in driving trends in
net usage upwards, even if the target cannot be reached.
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